Who Qualifies for GLP-1 Weight Loss Medication
The pattern is: mild during month 1, peak during month 2, substantial improvement by month 3, minimal from month 4 onward
In clinical trials of ADHD, weight loss occurred in: 3% to 4% of adults who took Vyvanse 9% of children who took Vyvanse 0% to 1% of adults and children who took a placebo (treatment containing no active drug) After 4 weeks of treatment, the average weight loss in people who took Vyvanse was: 2.8 pounds (lb) to 4.3 lb (1.3 kilograms [kg] to 2 kg) in adults 2.7 lb to 4.8 lb (1.2 kg to 2.2 kg) in children ages 13 to 17 years 0.9 lb to 2.5 lb (0.4 kg to 1.1 kg) in children ages 6 to 12 years The amount of weight lost depended on dose, with more weight loss seen in people who took higher doses of Vyvanse
"There is no standardization of the dosing, no standardization of safetyand there have been FDA reports of people ending up in the emergency room because of it." Patients should know exactly what they are being prescribed and whether it is FDA-approved
Worldwide inertia to the use of cardiorenal protective glucose-lowering drugs (SGLT2i and GLP-1RA) in high-risk patients with type 2 diabetes
Supplementary information Supplementary Figures and Tables (PDF 594 kb) PowerPoint slides Rights and permissions About this article Cite this article Muskiet, M., Tonneijck, L., Smits, M
